Search Results - robert abramovitch

4 Results Sort By:

Novel MmpL3 Inhibitor as a Treatment of Mycobacterium Tuberculosis

Executive SummaryMycobacterium Tuberculosis (Mtb) is the pathogen responsible for Tuberculosis. Standard TB treatments typically require four different drugs and a duration of six to nine months of treatment; however, there is still an evolution of drug-resistant Mtb. With not only Tuberculosis, but drug-resistant Tuberculosis causing upwards of 1.5...
Published: 6/4/2018   |   Inventor(s): Robert Abramovitch, Huiqing Zheng
Keywords(s):   Category(s): Medical, Biotechnology, Pharmaceutical

Novel Chemical Inhibitors of Mycobacterium Tuberculosis Targeting the DosRST Pathway – Tuberculosis Treatment

Executive SummaryTuberculosis (TB) is a potentially fatal infectious disease caused by the bacterium, Mycobacterium tuberculosis (Mtb). According to the Centers for Disease Control and Prevention (CDC), TB is one of the world’s deadliest diseases and responsible for upwards of 1.5 million deaths annually. TB is also a leading killer of HIV-infected...
Published: 5/24/2018   |   Inventor(s): Robert Abramovitch, Edmund Ellsworth
Keywords(s):   Category(s): Medical, Biotechnology, Pharmaceutical

Inhibition of the Mycobacterium Tuberculosis Virulence Using Ethoxzolamide

Executive SummaryTo address the pitfalls of traditional antibiotic tuberculosis therapies, such as the emergence of multi-drug resistant bacterial strains, alternative treatment strategies are currently being pursued. Researchers at Michigan State University (MSU) have developed a promising anti-virulence treatment strategy for Mycobacterium tuberculosis...
Published: 12/28/2016   |   Inventor(s): Robert Abramovitch, Benjamin Johnson, Christopher Colvin
Keywords(s):   Category(s): Medical, Pharmaceutical

Chemical Compounds that Limit Mycobacterium Tuberculosis Growth in Vitro or in Vivo

Executive SummaryMycobacterium tuberculosis (M. tuberculosis) causes the disease tuberculosis (TB) in humans.  Driven by the hypoxic environment of the granuloma, M. tuberculosis enters a persistent, non-replicating state that is recalcitrant to antibiotic therapy.  Treatment requires a multidrug, 6-9 month therapeutic regimen which has fueled the emergence...
Published: 10/14/2016   |   Inventor(s): Robert Abramovitch, Christopher Colvin, Benjamin Johnson
Keywords(s):   Category(s): Pharmaceutical, Medical